How effective is AHCC in clearing persistent HPV infections. What are the results of the latest phase II clinical trial on AHCC supplementation. How does AHCC modulate host immunity to combat high-risk HPV.

Understanding AHCC and Its Potential in HPV Treatment

AHCC, or Active Hexose Correlated Compound, is a proprietary extract derived from cultured lentinula edodes mycelia. This supplement has garnered significant attention in recent years due to its potential immune-modulating properties. Research has shown that AHCC may offer a range of therapeutic benefits, including enhanced antioxidant effects, anticancer activity, and the ability to modulate the immune system to combat both viral and bacterial infections.

The importance of exploring AHCC as a potential treatment for persistent HPV infections cannot be overstated. High-risk HPV infections that persist for more than two years significantly increase the risk of developing cancer. Currently, there is no systemic treatment available for these persistent infections, leaving patients and healthcare providers with limited options.

Why is AHCC being studied for HPV clearance?

AHCC is being investigated as a potential treatment for persistent HPV infections due to its unique immune-modulating properties. The supplement has shown promise in supporting the body’s natural defenses against various pathogens, including viruses. By enhancing the immune system’s ability to recognize and eliminate HPV-infected cells, AHCC may offer a non-invasive approach to clearing these stubborn infections.

The Journey from Pilot Studies to Phase II Clinical Trial

The road to investigating AHCC as a potential treatment for persistent HPV infections began with promising pilot studies. These initial investigations provided the foundation for more rigorous clinical trials, ultimately leading to the recent phase II study.

What did the pilot studies reveal about AHCC and HPV clearance?

Two pilot studies laid the groundwork for further research into AHCC’s potential to clear persistent HPV infections:

• In the first study, 8 women with persistent HPV infections were given a daily dose of 3g AHCC on an empty stomach. The results were encouraging, with 4 out of 8 women (50%) clearing their infections within 3 to 6 months of starting the supplementation.
• The second pilot study involved 9 women taking a lower dose of 1g AHCC daily on an empty stomach. The response rate was similar, with 4 out of 9 women (44%) confirming clearance of high-risk HPV persistent infections after 7 months of supplementation.

These preliminary findings provided the rationale for conducting a more comprehensive phase II clinical trial.

Breaking Down the Phase II Clinical Trial

The recent phase II study, conducted by Dr. Judith Smith and her team, represents a significant step forward in evaluating AHCC’s potential as a treatment for persistent HPV infections. This randomized, double-blind, placebo-controlled trial was designed to assess the efficacy, safety, and durability of AHCC supplementation in supporting the immune system’s ability to clear high-risk HPV infections.

How was the phase II clinical trial structured?

The study design included the following key elements:

• 50 women over the age of 30 with persistent HPV infections lasting more than two years were enrolled
• Participants were randomly assigned to two groups: one receiving AHCC and the other receiving a placebo
• The AHCC group took 3g of the supplement once daily on an empty stomach for six months, followed by a placebo for the remaining 6 months
• Evaluations were conducted every 3 months, including HPV-DNA and HPV-RNA testing, as well as blood samples to assess immune markers
• The trial lasted for a total of 12 months

Unveiling the Results: AHCC’s Impact on HPV Clearance

The results of the phase II clinical trial have generated considerable excitement in the medical community, offering hope for those struggling with persistent HPV infections.

What were the key findings of the AHCC phase II trial?

The study yielded several important results:

• Of the 41 women who completed the study, 14 out of 22 (63.6%) in the AHCC group successfully cleared their HPV infections
• The clearance rate of 63.6% represents a significant improvement over the natural clearance rate of persistent HPV infections
• AHCC supplementation was found to be safe and well-tolerated by the participants
• The study demonstrated a durability of response, with cleared infections remaining undetectable even after discontinuation of AHCC

These findings suggest that AHCC supplementation may be an effective and safe approach to support the immune system in clearing persistent high-risk HPV infections.

Exploring the Immune Modulation Effects of AHCC

One of the most intriguing aspects of the AHCC study is its potential impact on the immune system. By examining various immune markers throughout the trial, researchers gained valuable insights into how AHCC may be working to combat HPV infections.

How does AHCC affect immune markers?

The study evaluated several key immune markers, including:

• Interferon-alpha (IFNα)
• Interferon-beta (IFNβ)
• Interferon-gamma (IFNγ)
• IgG1 antibodies
• T-lymphocytes
• Natural killer (NK) cell levels

While the full analysis of these markers is ongoing, preliminary results suggest that AHCC may enhance the activity of certain immune components, particularly natural killer cells and T-lymphocytes. These cells play crucial roles in identifying and eliminating virus-infected cells, potentially explaining AHCC’s effectiveness in clearing HPV infections.

Implications for HPV Management and Cancer Prevention

The implications of this study extend far beyond the realm of HPV treatment. By offering a potential method to clear persistent infections, AHCC supplementation could play a significant role in reducing the risk of HPV-related cancers.

How might AHCC supplementation impact cancer prevention efforts?

The potential benefits of AHCC in cancer prevention are multifaceted:

• By clearing persistent HPV infections, AHCC may reduce the risk of cellular changes that lead to cancer development
• AHCC could provide a non-invasive alternative or complement to current screening and treatment methods
• The supplement’s immune-modulating effects may have broader applications in supporting overall health and cancer prevention

While more research is needed to fully understand the long-term impacts, these initial findings are promising for individuals at high risk of HPV-related cancers.

Comparing AHCC to Current HPV Management Strategies

To fully appreciate the potential of AHCC supplementation, it’s important to consider how it compares to existing approaches for managing persistent HPV infections.

How does AHCC supplementation differ from current HPV treatments?

Current treatment modalities for HPV-related lesions include:

• Cryotherapy
• Surgical excision
• Loop electrosurgical excisional procedure (LEEP)
• Cold knife conization

While these treatments have a high response rate of about 80%, they are invasive and often associated with recurrent lesions. In contrast, AHCC supplementation offers several potential advantages:

• Non-invasive approach
• Potential for systemic effects, addressing HPV infections throughout the body
• Possibility of preventing the development of precancerous lesions
• Lower risk of side effects compared to surgical interventions

These differences highlight the potential of AHCC to revolutionize the management of persistent HPV infections.

Future Directions: What’s Next for AHCC Research?

While the results of the phase II trial are encouraging, they also pave the way for further research into the potential of AHCC as a treatment for persistent HPV infections.

What are the next steps in AHCC research?

Several avenues for future research and development are being considered:

• Larger-scale clinical trials to confirm the efficacy and safety of AHCC supplementation
• Studies exploring optimal dosing regimens and duration of treatment
• Investigations into the potential of AHCC for other types of viral infections
• Research on combining AHCC with other treatments or preventive strategies
• Long-term follow-up studies to assess the durability of HPV clearance and cancer prevention effects

These future studies will help to further elucidate the potential of AHCC in managing persistent HPV infections and reducing cancer risk.

The journey of AHCC from bench to bedside represents a promising development in the fight against persistent HPV infections and related cancers. As research continues, this natural supplement may offer new hope for millions of individuals affected by high-risk HPV infections worldwide. While more studies are needed to fully understand its mechanisms and long-term effects, the current evidence suggests that AHCC supplementation could become a valuable tool in the arsenal against HPV-related diseases.

As we await further developments in this field, it’s important for individuals with persistent HPV infections to consult with their healthcare providers about the potential benefits and risks of AHCC supplementation. The ongoing research into AHCC serves as a reminder of the power of innovative approaches in addressing complex health challenges, and the importance of continued scientific inquiry in improving patient outcomes.

AHCC Clears HPV Infections in Phase II Trial

People who have high-risk HPV fear getting cancer, but don’t know how to prevent it. The only advice doctors can provide is to support the immune system by eating well, sleeping well, and reducing stress. In support groups, survivors of HPV cancers express great fear that their HPV will lead to cancer yet again. So, for people who have high-risk HPV, any research on a supplement that supports the immune system’s ability to clear persistent HPV infections is profoundly significant. This new phase II study showing that AHCC is 58% effective at clearing persistent HPV infections provides hope for those of us who have high-risk HPV.

A persistent HPV infection is defined as one that lasts for more than two years, and the longer an HPV infection is active, the more likely it is that abnormal cancer cells will form. Although most people clear HPV infections naturally in 2 years if their immune system is strong, not everyone has a strong immune system. The immune system can be compromised by poor diet, insufficient sleep, stress, or just age. About 10% of people with HPV infections have persistent infections that last for more than 2 years. Since persistent high-risk HPV infections are the most likely to cause cancer, it is important to study these cases.

To date, there is no systemic treatment for persistent HPV infections. Current treatment modalities rely on early detection in vaginal PAP smears followed by treatments like cryotherapy, surgical excision, loop electrosurgical excisional procedure (LEEP), or cold knife conization. Although these treatments have a high response rate of 80%, patients will frequently have recurrent lesions. In addition, there is not yet an established medical protocol for screening and treating HPV infections in other parts of the body, like the anus. The Anchor Study, for example, has shown that screening for HPV and treating precancerous cells can lower the incidence of anal cancer. But this type of screening is in its infancy and only available in select locations. It would therefore be better to prevent these cell changes from happening in the first place. This phase II study of AHCC supplementation provides hope that persistent HPV infections can be prevented from progressing to cancer.

What Is AHCC?

The AHCC supplement is a proprietary, standardized extract of cultured lentinula edodes mycelia that has been shown to have unique immune modulatory benefits. Several animal and human studies have reported a variety of therapeutic effects, including enhanced antioxidant effects, anticancer activity, and modulation of the immune system to prevent the infectious processes of both viral and bacterial infections.  This new clinical trial suggests that AHCC can also help the immune system clear persistent HPV infections.

Pilot Studies of AHCC to Clear HPV Infections

AHCC originally showed promise in two pilot studies. In one study of women with persistent HPV infections, 4 out of the 8 women who remained in the study (50%) cleared their persistent HPV infection between 3 to 6 months after starting a 3g daily dose of AHCC on an empty stomach.  In a second pilot study, women were given 1g of AHCC a day on an empty stomach and showed a similar response rate: 4 out of the 9 women (44%) confirmed clearance of high-risk HPV persistent infections after 7 months of supplementation. These pilot studies provided the rationale to move forward with a phase II trial of AHCC to clear persistent HPV infections.

The New Phase II Study

Our medical advisory board member Judith Smith conducted this phase II randomized, double-blind, placebo-controlled study with a post unblinded study. This trial was reviewed and approved by the University of Texas Health Sciences Center Institutional Review Board. The objective of the study was to determine the efficacy, safety, and durability of AHCC supplementation for 6 months to support the host immune system to clear high-risk HPV infections.

Fifty women over age 30 with persistent HPV infections that had lasted more than two years were studied for 12 months. Patients were randomized into two groups: one group took AHCC 3g by mouth once daily on an empty stomach for six months followed by a placebo for the remaining 6 months. The control group was given a placebo. Every 3 months patients were evaluated with HPV-DNA and HPV-RNA testing and with a blood sample to evaluate a panel of immune markers including: interferon‐alpha(INN), interferon‐beta (IFNβ), interferon‐gamma (IFN), IgG1, T‐lymphocytes, and natural killer(NK) cell levels.

Of the 41 women who completed the study, fourteen (63.6%) of the 22 patients in the AHCC supplementation arm were HPV-RNA/HPV-DNA negative after six months, and 64.3% (9/14) achieved a durable response defined as also being HPV-RNA/HPV-DNA negative 12 months after the supplementation ended. In contrast, in the placebo arm of the study, only two (10.5%) of 19 patients were HPV negative at 12 months. An additional twelve patients completed the un-blinded study and 50% were HPV-RNA/HPV-DNA negative after six months of AHCC supplementation.

Combining all 34 participants that received AHCC supplementation gives an overall response rate of 58.8% that cleared HPV persistent infections.

Conclusions 

Results from this phase II study demonstrated that AHCC 3g once daily on an empty stomach was effective in supporting the host immune system’s elimination of persistent HPV infections and was well tolerated with no significant adverse side effects reported.

Directions for Further Research

 An additional finding of the study was that suppression of IFNβ to less than 20pg/mL correlated with an increase in T‐lymphocytes and IFN and durable clearance of HPV infections in women that received AHCC supplementation. This merits further evaluation as a clinical tool for monitoring patients with HPV infections. The duration of AHCC supplementation required beyond first negative result also needs more evaluation to optimize success for durable outcomes.

AHCC is Unique

It’s important to distinguish AHCC from other medicinal mushrooms. AHCC is the only medicinal mushroom that has been clinically demonstrated to help eradicate HPV. It is not interchangeable with other medicinal mushrooms because it has been specially developed and processed to maximize its immune-boosting capacity. AHCC is made by cell culturing a specific subspecies of mushroom identified by Japanese scientists several decades ago to have the greatest ability to increase natural killer cell activity. Its molecular weight has been reduced using a patented enzymatic process to improve its absorption and clinical efficacy. Every batch of AHCC is subjected to DNA pattern testing to confirm its identity (in other words, to ensure it is genuine AHCC). These innovations make AHCC unique among medicinal mushrooms.

AHCC is available from multiple nutritional supplement companies, but it is important to steer clear of fake products using different names yet claiming similar benefits. Only genuine AHCC® has been clinically tested and found to help clear HPV.

Click to read the full study

Here is a list of genuine AHCC products.

AHCC® is a registered trademark of the Amino Up Company

A Note for Anal Cancer Survivors

Because this study was conducted on women with vaginal HPV infections, we reached out to Dr. Romesser, a radiation oncologist specializing in anal cancer at Memorial Sloan Kettering, to ask about anal cancer survivors and AHCC. No side effects from AHCC were reported in women with vaginal HPV in the study described above; however, there is some anecdotal indication that there may be mild side effects for anal cancer survivors. Dr. Romesser has noticed that some anal cancer survivors experience side effects like anal itching when they start taking AHCC. Therefore, he recommends that anal cancer patients who have recently had treatment, wait to take AHCC until all the side effects from treatment have subsided.  It also seems that for some anal cancer survivors, the side effects from taking AHCC go away after a few weeks. It might be worthwhile to continue taking AHCC for a few weeks despite any side effects in case the side effects subside.

Can AHCC Cure HPV & How Much Should I Take?

The human papillomavirus, otherwise known as HPV, is a common virus that contributes to an estimated 630,000 new cancer cases annually worldwide (1). Cancer of the cervix represents over 80 percent of the cases caused by the virus. According to the CDC, other types of cancers have been attributed to HPV, such as 70 percent of oropharyngeal cancer, 90 percent of anal cancer, and 70 percent of vaginal and vulvar cancer (2). There are 100 different types of HPV, many of which do not cause cancer. However, researchers have identified 6 HPV types as definite human carcinogens (3).

Is there any way to help get rid of HPV infections? Read on to learn more about how HPV affects the body and why a supplement called AHCC may be able to help.

Do HPV Infections Go Away?

HPV often disappears from Pap test results within about two years, often without any treatment. While this scenario happens in the majority of cases, it does not always occur that way.

In some instances of HPV infections, the virus stays dormant and surfaces many years later. In these cases, the infections never really get resolved, and HPV ends up lingering for a long time. The body has a particularly hard time responding to the virus in people with weakened immune systems. When the infection persists, the potential for more serious complications increases, leading to the incidence of cervical cancer, genital warts, and other issues.

What’s the Most Effective Approach to Treat HPV?

Optimal immune function is essential to defend against pathogenic invaders like HPV. While there is no known cure for HPV infections, strengthening the immune system with natural substances such as AHCC has shown promising results.

AHCC is a cultured extract of various species of medicinal mushroom mycelia (roots). It has an immune-boosting effect that enables it to assist the body in eradicating the virus. This extract enhances immune function by increasing the number and activity of natural killer cells and other immune cells.

Over 30 human clinical trials looked at the effectiveness of AHCC in the treatment of many severe conditions, such as head and neck cancer, liver cancer, and HPV-positive cervical cancer. The results of these studies have been so impressive that some of the most prestigious institutions around the world have studied AHCC.

A pilot study at the University of Texas Health Science Center at Houston followed 10 HPV-positive women who took 3 grams of AHCC once daily for three months, and up to six months. At the end of the trial, 50% of the women tested negative for HPV (4). These are incredibly encouraging results considering that there is currently no cure for the condition.

What Dosage of AHCC Should I Take to Eradicate HPV?

Based on the best available scientific evidence, 3 grams of HPV cure AHCC. Daily AHCC appears to be an effective AHCC HPV dosage for the eradication of HPV. Treatment with this supplement makes the virus dormant in the body, so to achieve continuous suppression, it is important to continue taking the supplement indefinitely.
Editor’s pick:  Active Hexose Correlated Compound by HPD Rx This supplement is clinically tested and made from the highest quality ingredients.  

Sources

1. Worldwide burden of cancer attributable to HPV by site, country and HPV type: National Institutes of Health, 2017.
2. HPV-Associated Cancer Statistics: Centers for Disease Control and Prevention, 2018.
3. Global burden of human papillomavirus and related diseases: National Institutes of Health, 2012.
4. Mushroom extract, AHCC, helpful in treating HPV: ScienceDaily, 2014.

Discount on AHCC – Joy of soul and body

I’m halfway through my second can now, and although this drug should be taken longer, I’ll report back now because of the discount. The drug is expensive and 10% if you buy several jars can be a significant savings.

I drink at the maximum dose presented on the website of 750 mg per capsule (there are 250 mg and 500 mg). Take 2 capsules in the morning on an empty stomach with a glass of water.
AHCC is an abbreviation of the English words (Active Hemi-Cellulose Compound) (Active Hexose Correlation Complex).
Produced from medicinal mushrooms by a proprietary mushroom mycelium culturing process. clinical efficacy.

AHCC technology was developed by the Japanese company Amino UP Chemical Co. Ltd. (Sapporo) and Dr. Toshihiko Okamoto from the Faculty of Pharmacology, University of Tokyo in 1989. The process looks like this. A hybrid of shiitake, maitake and reishi is grown in a liquid nutrient medium based on brown rice. The shell of rice grains is rich in cellulose. Shiitake, maitake, and reishi mushrooms lack chlorophyll and, unlike plants, are not capable of photosynthesis. So they eat like animals. They release enzymes into the environment, digest the nutrients there, and absorb them. During this process, rice cellulose, a high molecular weight polysaccharide, is broken down by fungal enzymes (carbohydrases) into small fragments – oligosaccharides. After a certain period of cultivation, the mushroom material with fermentation products is centrifuged, concentrated and subjected to dry freezing. Then it is packaged in capsules. This information is googled, I am not a doctor and I do not understand this, who is interested there is a lot of information in all languages ​​..

My impressions after 1.5 months of taking 2 capsules per day (1500 mg).
I started taking this supplement during a sluggish flu, I can’t say that I was cured right away, it just took a long time, but I endured it on my feet.
In the reviews I read that many papillomavirus passes after taking AHCC. I don’t know for sure whether I have it or not, I didn’t do any tests, but there are a few small ones on my body, they haven’t gone anywhere, well, maybe they’ve become a little less ..
In general, I drink in a prophylactic dose before the autumn-winter season. From what I can note, this is a good mood, i.e. there are mental improvements and no fatigue, although I sleep very little. Usually during the day I want to sleep terribly, besides I am a hippotonist. Now in this regard I feel like a man, despite the difficult, busy period, perhaps the drug affects the pressure. I believe in the usefulness of this complex and taking advantage of the discount, I will buy more .. The price is unfortunately high .. (The capsules themselves are of a standard size, they are swallowed easily. The instructions do not say, but there is a general recommendation to drink mushroom complexes with 1-2 glasses of water in 30-40 minutes before meals

AHCC instructions for use

AHCC recommended doses.

1. Doses for disease prevention:

AHCC 1000-3000 mg or 2-6 capsules per day in three divided doses. Children for the purpose of prevention – 1 capsule 1 time per day.

2. Support in the treatment of cancer, prevention of side effects of anti-cancer therapy:

AHCC 3000-6000 mg or 6-12 capsules per day.

The Association for the Study of AHCC recommends that AHCC support the immune system in all cancers except blood disorders.

ANSS: indications

– Benign and malignant neoplasms.

– Immunodeficiency.

– Hepatitis B and C.

– Diabetes.

– Herpes.

– Skin viral diseases.

– Atopic dermatitis.

– Weakened immunity.

– Chronic fatigue syndrome.

– Urogenital infections.

The drug should not be taken in case of individual intolerance to at least one of the components, as well as in case of blood diseases.

AHCC is being investigated in the United States, China, Korea, Japan and Thailand. AHCC has been used as a supplement for patients with cancer, AIDS, hepatitis C, diabetes, hypertension, and autoimmune diseases. There are claims for its use in the treatment of wounds, stomach ulcers, gingivitis, fatigue syndrome, parasites and multiple sclerosis.
Backed by over 20 human clinical studies, AHCC is used in over 1,000 clinics worldwide. AHCC research has been conducted at some of the world’s most renowned research institutions, including highly regarded Ivy League universities. The uniqueness of the drug is that it changes both the innate and adaptive immune response.

My code is KFG537 gives a 5% discount on any order, thanks if you use it).

Tags: for health, for health-strengthening immunity, discounts/promotions, advise
first cheaper
by name

Japanese AHCC

The use of high molecular weight polysaccharides for the treatment of cancer was first developed by the Japanese company Amino UP Chemical Co. Ltd. A mixture based on shiitake, maetake and reishi mushrooms is a natural AHCC complex.

Revolutionary formula works with polysaccharides, amino acids and minerals. It is prescribed for pathologies of internal organs, oncological diseases.

AHCC preparation: composition and features

1. Shiitake. Components are used at increased risks of cancer and for the treatment of cancer patients. Mycelium is relevant for immunodeficiency syndrome, hepatitis. Penetrating into the cells, shiitake curb the progression of the disease, reducing the manifestation of symptoms.

2. Maetaki (dancing mushroom). Immunomodulating properties prevent the degeneration of benign formations. Also, the ANSS ingredient normalizes blood pressure, prevents the development of hypertension, and maintains blood sugar levels. By activating macrophages, they stimulate the reaction of cell defense.

3. Reishi. It is relevant for oncological pathologies of the esophagus, liver, pancreas, lungs, bone tissue and brain. It is used in medicine for the treatment of joints, respiratory problems.

Indications for the use of AHCC

According to the opinions of specialists and patients, AHCC is necessary as an additional support in diagnosing:

• malignant and benign neoplasms;

• immunodeficiency virus, immunocompromised;

• type 2 diabetes;

• liver diseases, including hepatitis B and C;

• skin diseases, herpes and other viral infections;

• irritability, chronic fatigue syndrome.

Properties Additive AHCC

The effectiveness of the drug has been proven by laboratory tests. The dose for prevention is 1000-300 mg of the active substance. When using a cancer support supplement, the dosage is increased to 3000-6000 mg. Benefits:

• Polysaccharides have a beneficial effect on the links of cellular immunity, activate T-helpers when the components are absorbed by macrophages;

• Stimulate the natural reproduction of T-helpers in the body;

• ANSS has a direct antitumor effect, inhibiting and reducing the growth of neoplasms that suppress the effective functioning of the immune system;

• Promotes the release of interferon-gamma, necessary for the activation of macrophages;

• Protects the liver from the negative effects of drugs, chemotherapy and radiotherapy;

• Performs the task of a powerful antioxidant during the rehabilitation period.